跳至主要内容
临床试验/NCT01559116
NCT01559116已完成3 期

Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]

Boehringer Ingelheim29 个研究点 分布在 7 个国家目标入组 219 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
219
试验地点
29
主要终点
Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.

研究概览

简要总结

The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

tiotropium+olodaterol FDC high dose

Experimental

tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

tiotropium low dose

Active Comparator

tiotropium low dose; 2 inhalations once daily (a.m. dosing)

干预措施: tiotropium (Drug)

tiotropium low dose

Active Comparator

tiotropium low dose; 2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

tiotropium high dose

Active Comparator

tiotropium high dose; 2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

olodaterol

Active Comparator

one dose only; 2 inhalations once daily (a.m. dosing)

干预措施: olodaterol (Drug)

tiotropium+olodaterol FDC low dose

Experimental

tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)

干预措施: tiotropium + olodaterol (Drug)

tiotropium+olodaterol FDC low dose

Experimental

tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

tiotropium+olodaterol FDC high dose

Experimental

tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)

干预措施: tiotropium + olodaterol (Drug)

tiotropium high dose

Active Comparator

tiotropium high dose; 2 inhalations once daily (a.m. dosing)

干预措施: tiotropium (Drug)

olodaterol

Active Comparator

one dose only; 2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

placebo

Placebo Comparator

2 inhalations once daily (a.m. dosing)

干预措施: Placebo (Drug)

placebo

Placebo Comparator

2 inhalations once daily (a.m. dosing)

干预措施: Respimat (Device)

结局指标

主要结局

Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.

时间窗: day 1 and week 6

Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 24 h post-dose, using the trapezoidal rule, divided by the duration (24 h) to report in litres. Mean is actually the Adjusted mean. The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within-patient variation and Kenward-Roger approximation of denominator degrees of freedom.

次要结局

  • FEV1 AUC0-12h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • FEV1 AUC12-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • Peak(0-3h) FEV1 Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • Trough FEV1 Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • FVC AUC0-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • FVC AUC0-12h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • FVC AUC12-24h Response [L] After 6 Weeks Treatment.(day 1 and week 6)
  • Trough FVC Response [L] After 6 Weeks Treatment.(day1 and week 6)
  • Peak (0-3h) FVC Response [L] After 6 Weeks Treatment.(day 1 and week 6)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验